Regional and network-level convergent structural effects of electroconvulsive therapy in depression: a neuroimaging meta-analysis.

J Psychiatr ResMay 13, 2026 (epub)
Clinical ResearchPsychiatry

Huiqing Meng, Yahui Yang, Qian Cui et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis examined the structural effects of electroconvulsive therapy (ECT) on brain regions in patients with depression. The study analyzed eleven neuroimaging studies and found that ECT significantly increased whole-brain gray matter volume (GMV) in specific areas, including the bilateral hippocampus and amygdala. The findings suggest a relationship between ECT efficacy and neuroplastic changes in limbic-subcortical networks.

Key findings

  • ECT increased GMV in the bilateral hippocampus, parahippocampus, and amygdala.
  • Convergent structural connectivity was observed with limbic and subcortical networks.
  • No neurotransmitter receptors or transporters were significantly over or under expressed in the ALE clusters.

Why it matters

Understanding the structural effects of ECT on brain regions can enhance the knowledge of its neurobiological mechanisms in treating depression, potentially guiding future therapeutic strategies and research.

Source

PubMed · PMID 42140097

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.